News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanopeutics Signs Exclusive Technology Agreement With HemCon Medical Technologies, Inc. For Military Market


1/18/2007 10:40:44 AM

PORTLAND, Oregon and DUBLIN Ireland, January 18 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets, today announces that Nanopeutics(TM) s.r.o., ("Nanopeutics"), the Company's specialist subsidiary dedicated to the commercialisation of Nanospider(TM) technology for the global woundcare market, has signed an exclusive technology and product concept development agreement with HemCon Medical Technologies, Inc. the haemorrhage control market leaders in military markets.

The successful conclusion to the development work, which has already commenced following successful initial product tests, is expected to lead to a licence and supply agreement for a range of chitosan based Nanospider(TM) woundcare technologies and products for exclusively military market usage.

John W. Morgan, President & CEO HemCon Medical Technologies commented:

"As the leader and key innovator in hemorrhage control in the military market, HemCon is dedicated to a significant R&D effort on our platform technology of advanced chitosan materials. Initial product tests on Nanospider(TM) spun chitosan are very encouraging and we are excited to be working with the Nanopeutics and Alltracel teams on the development of this breakthrough technology for the specialist military markets"

Alltracel CEO Tony Richardson commented:

"This collaboration with HemCon for the military market is another significant milestone for Nanopeutics' advanced woundcare technology. HemCon is a true woundcare innovator with unrivalled experience in the specialist military market and we are delighted to be teaming with them on this exciting market opportunity. "

For Further Information Contact: Dublin: Denise Cronin Alltracel: +353-1-235-2162 press@alltracel.com Nanopeutics: +420-489-209-127 Liberec: Pavel Novotny press@nanopeutics.net London: Deborah Scott Financial Dynamics: +44-0207-831-3113 New York: Sean Leous Financial Dynamics: +1-212-850-5626 Notes to Editors follow:

HemCon Medical Technologies, Inc. ("HemCon") (www.hemcon.com) founded in 2001, develops, manufactures, and markets innovative technologies to control bleeding and infection resulting from trauma or surgery.

HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance.

The HemCon(R) Bandage was developed in collaboration with the Oregon Medical Laser Center and Providence St. Vincent's Hospital.

HemCon's manufacturing and corporate headquarters are located in Portland, Oregon.

Nanopeutics(TM) s.r.o. ("Nanopeutics") (www.nanopeutics.net) is the specialist Alltracel subsidiary formed as part of a joint venture with Elmarco s.r.o. dedicated to the commercialisation of Nanospider(TM) technology for the global professional and consumer woundcare markets.

Nanopeutics, headquartered in Liberec in the Czech Republic and operating internationally, has been licensed and/or assigned the relevant woundcare and Nanospider(TM) intellectual property and patents. Nanospider(TM) is the novel patented process for spinning polymers into nano-scale fibres for a range of industrial, chemical, micro-electronic and bio-medical applications. The Nanospider(TM) technology has been recognised internationally as a major breakthrough in the mass production of nanofibre materials.

Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc ("Alltracel") is a Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets.

With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China.

Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001.

Alltracel' has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focussed on its markets.

In the consumer Woundcare market m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel's patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent and is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide.

Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following over two years of scientific research including in vitro, pre-clinical and clinical trials, indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products.

The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods.

HemCon(R) is a registered trademark of HemCon Medical Technologies, Inc.

m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.

Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by Nanopeutics s.r.o.

Alltracel Pharmaceuticals Plc.

CONTACT: Alltracel: +353-1-235-2162, press@alltracel.com, Nanopeutics:+420-489-209-127, press@nanopeutics.net, Financial Dynamics:+44-0207-831-3113, Financial Dynamics: +1-212-850-5626


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES